The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia

Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia

(2011) Daniela Alberati et al.   NEUROPHARMACOLOGY

Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis

(2010) Guochuan Tsai et al.   CURRENT PHARMACEUTICAL DESIGN

A METHOD FOR QUANTITATIVE SCORING OF THE FARNSWORTH PANEL D-15

(2009) K. J. BOWMAN   ACTA OPHTHALMOLOGICA

The Glycine Reuptake Inhibitor Org 25935 Interacts With Basal and Ethanol-Induced Dopamine Release in Rat Nucleus Accumbens

(2009) Helga Höifödt Lidö et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia

(2009) Christine E Marx et al.   NEUROPSYCHOPHARMACOLOGY

Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial

(2009) Grigori Joffe et al.   SCHIZOPHRENIA RESEARCH

Glycine Transport Inhibitors and the Treatment of Schizophrenia

(2008) Daniel C. Javitt   BIOLOGICAL PSYCHIATRY

Inhibitors of GlyT1 Affect Glycine Transport via Discrete Binding Sites

(2008) M. Mezler et al.   MOLECULAR PHARMACOLOGY